T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity

As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising antibody therapy for various kinds of cancer. In general, T-BsAbs have dual-binding specificity to a tumor-associated antigen and a CD3 subunit forming a complex with the TCR. This enables T-BsAbs to crosslink tu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daisuke Kamakura, Ryutaro Asano, Masahiro Yasunaga
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	T cell bispecific antibody T-BsAb pharmacokinetics T cell redirection mechanism of action drug development Medicine R Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/af23fae792844ddd887492ea00c2d6d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:af23fae792844ddd887492ea00c2d6d8
record_format	dspace
spelling	oai:doaj.org-article:af23fae792844ddd887492ea00c2d6d82021-11-25T18:39:54ZT Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity10.3390/ph141111721424-8247https://doaj.org/article/af23fae792844ddd887492ea00c2d6d82021-11-01T00:00:00Zhttps://www.mdpi.com/1424-8247/14/11/1172https://doaj.org/toc/1424-8247As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising antibody therapy for various kinds of cancer. In general, T-BsAbs have dual-binding specificity to a tumor-associated antigen and a CD3 subunit forming a complex with the TCR. This enables T-BsAbs to crosslink tumor cells and T cells, inducing T cell activation and subsequent tumor cell death. Unlike immune checkpoint inhibitors, which release the brake of the immune system, T-BsAbs serve as an accelerator of T cells by stimulating their immune response via CD3 engagement. Therefore, they can actively redirect host immunity toward tumors, including T cell recruitment from the periphery to the tumor site and immunological synapse formation between tumor cells and T cells. Although the low immunogenicity of solid tumors increases the challenge of cancer immunotherapy, T-BsAbs capable of immune redirection can greatly benefit patients with such tumors. To investigate the detailed relationship between T-BsAbs delivery and their T cell redirection activity, it is necessary to determine how T-BsAbs deliver antitumor immunity to the tumor site and bring about tumor cell death. This review article discusses T-BsAb properties, specifically their pharmacokinetics, redirection of anticancer immunity, and local mechanism of action within tumor tissues, and discuss further challenges to expediting T-BsAb development.Daisuke KamakuraRyutaro AsanoMasahiro YasunagaMDPI AGarticleT cell bispecific antibodyT-BsAbpharmacokineticsT cell redirectionmechanism of actiondrug developmentMedicineRPharmacy and materia medicaRS1-441ENPharmaceuticals, Vol 14, Iss 1172, p 1172 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	T cell bispecific antibody T-BsAb pharmacokinetics T cell redirection mechanism of action drug development Medicine R Pharmacy and materia medica RS1-441
spellingShingle	T cell bispecific antibody T-BsAb pharmacokinetics T cell redirection mechanism of action drug development Medicine R Pharmacy and materia medica RS1-441 Daisuke Kamakura Ryutaro Asano Masahiro Yasunaga T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
description	As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising antibody therapy for various kinds of cancer. In general, T-BsAbs have dual-binding specificity to a tumor-associated antigen and a CD3 subunit forming a complex with the TCR. This enables T-BsAbs to crosslink tumor cells and T cells, inducing T cell activation and subsequent tumor cell death. Unlike immune checkpoint inhibitors, which release the brake of the immune system, T-BsAbs serve as an accelerator of T cells by stimulating their immune response via CD3 engagement. Therefore, they can actively redirect host immunity toward tumors, including T cell recruitment from the periphery to the tumor site and immunological synapse formation between tumor cells and T cells. Although the low immunogenicity of solid tumors increases the challenge of cancer immunotherapy, T-BsAbs capable of immune redirection can greatly benefit patients with such tumors. To investigate the detailed relationship between T-BsAbs delivery and their T cell redirection activity, it is necessary to determine how T-BsAbs deliver antitumor immunity to the tumor site and bring about tumor cell death. This review article discusses T-BsAb properties, specifically their pharmacokinetics, redirection of anticancer immunity, and local mechanism of action within tumor tissues, and discuss further challenges to expediting T-BsAb development.
format	article
author	Daisuke Kamakura Ryutaro Asano Masahiro Yasunaga
author_facet	Daisuke Kamakura Ryutaro Asano Masahiro Yasunaga
author_sort	Daisuke Kamakura
title	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
title_short	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
title_full	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
title_fullStr	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
title_full_unstemmed	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
title_sort	t cell bispecific antibodies: an antibody-based delivery system for inducing antitumor immunity
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/af23fae792844ddd887492ea00c2d6d8
work_keys_str_mv	AT daisukekamakura tcellbispecificantibodiesanantibodybaseddeliverysystemforinducingantitumorimmunity AT ryutaroasano tcellbispecificantibodiesanantibodybaseddeliverysystemforinducingantitumorimmunity AT masahiroyasunaga tcellbispecificantibodiesanantibodybaseddeliverysystemforinducingantitumorimmunity
_version_	1718410857751248896

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity

Ejemplares similares